AP3277A - Gene encoding human glucokinase mutant, enzyme encoded by the same, recombinant vectors and hosts, pharmaceutical compositions and uses thereof, methods for treating and preventing diseases - Google Patents
Gene encoding human glucokinase mutant, enzyme encoded by the same, recombinant vectors and hosts, pharmaceutical compositions and uses thereof, methods for treating and preventing diseasesInfo
- Publication number
- AP3277A AP3277A AP2011005814A AP2011005814A AP3277A AP 3277 A AP3277 A AP 3277A AP 2011005814 A AP2011005814 A AP 2011005814A AP 2011005814 A AP2011005814 A AP 2011005814A AP 3277 A AP3277 A AP 3277A
- Authority
- AP
- ARIPO
- Prior art keywords
- hosts
- treating
- methods
- pharmaceutical compositions
- gene encoding
- Prior art date
Links
- 108090000790 Enzymes Proteins 0.000 title 1
- 102000004190 Enzymes Human genes 0.000 title 1
- 101000840558 Homo sapiens Hexokinase-4 Proteins 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 239000013598 vector Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
- C12Y207/01002—Glucokinase (2.7.1.2)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200910000087 | 2009-01-07 | ||
PCT/CN2010/070038 WO2010078842A1 (zh) | 2009-01-07 | 2010-01-06 | 人葡萄糖激酶突变体编码基因、其编码的酶、重组载体及宿主、其药物组合物、应用以及预防和治疗疾病的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
AP2011005814A0 AP2011005814A0 (en) | 2011-08-31 |
AP3277A true AP3277A (en) | 2015-05-31 |
Family
ID=42316263
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AP2011005814A AP3277A (en) | 2009-01-07 | 2010-01-06 | Gene encoding human glucokinase mutant, enzyme encoded by the same, recombinant vectors and hosts, pharmaceutical compositions and uses thereof, methods for treating and preventing diseases |
Country Status (21)
Country | Link |
---|---|
US (1) | US9029142B2 (xx) |
EP (1) | EP2388317B1 (xx) |
JP (1) | JP5721637B2 (xx) |
KR (1) | KR101300540B1 (xx) |
CN (1) | CN102272296B (xx) |
AP (1) | AP3277A (xx) |
AU (1) | AU2010204379B2 (xx) |
BR (1) | BRPI1006104B8 (xx) |
CA (1) | CA2749180C (xx) |
DK (1) | DK2388317T3 (xx) |
EA (1) | EA024878B1 (xx) |
ES (1) | ES2649021T3 (xx) |
HU (1) | HUE035110T2 (xx) |
IL (1) | IL213750A (xx) |
MA (1) | MA33034B1 (xx) |
MX (1) | MX2011007263A (xx) |
NZ (1) | NZ593893A (xx) |
PT (1) | PT2388317T (xx) |
SG (1) | SG172851A1 (xx) |
WO (1) | WO2010078842A1 (xx) |
ZA (1) | ZA201105209B (xx) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102272147B (zh) | 2008-12-29 | 2017-09-12 | 特尔哈肖梅尔医学研究基础设施和服务有限公司 | 用于防止细胞粘附的肽和组合物及其使用方法 |
EA024878B1 (ru) | 2009-01-07 | 2016-10-31 | Хайдун Хуан | Ген, кодирующий мутантную глюкокиназу человека, отличающуюся увеличенной стабильностью, и его применение для контроля глюкозы в крови или предупреждения и лечения нарушений углеводного обмена |
WO2013117776A1 (es) * | 2012-02-08 | 2013-08-15 | Fundación Pública Andaluza Progreso Y Salud | Enzimas glucocinasas con actividad aumentada y su uso en el tratamiento y/o prevención de la diabetes mellitus |
US9171343B1 (en) | 2012-09-11 | 2015-10-27 | Aseko, Inc. | Means and method for improved glycemic control for diabetic patients |
US9897565B1 (en) | 2012-09-11 | 2018-02-20 | Aseko, Inc. | System and method for optimizing insulin dosages for diabetic subjects |
US9233204B2 (en) | 2014-01-31 | 2016-01-12 | Aseko, Inc. | Insulin management |
US9486580B2 (en) | 2014-01-31 | 2016-11-08 | Aseko, Inc. | Insulin management |
WO2016069475A1 (en) | 2014-10-27 | 2016-05-06 | Aseko, Inc. | Subcutaneous outpatient management |
US11081226B2 (en) | 2014-10-27 | 2021-08-03 | Aseko, Inc. | Method and controller for administering recommended insulin dosages to a patient |
AU2016308953B2 (en) | 2015-08-20 | 2020-09-10 | Glytec, Llc | Diabetes management therapy advisor |
CN110564777B (zh) * | 2019-09-23 | 2021-09-10 | 北京希诺谷生物科技有限公司 | 糖尿病疾病模型犬的建立方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002049423A1 (es) * | 2000-12-20 | 2002-06-27 | Universitat Autonoma De Barcelona | Utilizacion conjunta del gen de la insulina y del gen de la glucoquinasa en el desarrollo de aproximaciones terapeuticas para la diabetes mellitus |
WO2006043036A2 (en) * | 2004-10-19 | 2006-04-27 | The University Of Newcastle | Treatment of diabetes |
US20070219346A1 (en) * | 2002-04-22 | 2007-09-20 | Mcgill University | Glucose sensor and uses thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001511353A (ja) * | 1997-07-24 | 2001-08-14 | バレンティス・インコーポレーテッド | Ghrhの発現システムおよび使用法 |
US6689600B1 (en) * | 1998-11-16 | 2004-02-10 | Introgen Therapeutics, Inc. | Formulation of adenovirus for gene therapy |
WO2005052132A2 (en) * | 2003-11-24 | 2005-06-09 | Exelixis, Inc | Mbms as modifiers of branching morphogenesis and methods of use |
EP1890708A4 (en) * | 2005-06-01 | 2009-07-15 | Biotec Inst For Internat | GLUCOSE INDUCIBLE INSULIN EXPRESSION AND METHODS OF TREATING DIABETES |
WO2009021276A1 (en) * | 2007-08-10 | 2009-02-19 | University Of Technology, Sydney | Cells genetically modified to comprise pancreatic islet glucokinase and uses thereof |
EA024878B1 (ru) | 2009-01-07 | 2016-10-31 | Хайдун Хуан | Ген, кодирующий мутантную глюкокиназу человека, отличающуюся увеличенной стабильностью, и его применение для контроля глюкозы в крови или предупреждения и лечения нарушений углеводного обмена |
-
2010
- 2010-01-06 EA EA201170917A patent/EA024878B1/ru unknown
- 2010-01-06 NZ NZ59389310A patent/NZ593893A/xx unknown
- 2010-01-06 AP AP2011005814A patent/AP3277A/xx active
- 2010-01-06 CN CN2010800041374A patent/CN102272296B/zh active Active - Reinstated
- 2010-01-06 MX MX2011007263A patent/MX2011007263A/es active IP Right Grant
- 2010-01-06 EP EP10729101.5A patent/EP2388317B1/en active Active
- 2010-01-06 SG SG2011048972A patent/SG172851A1/en unknown
- 2010-01-06 CA CA2749180A patent/CA2749180C/en active Active
- 2010-01-06 JP JP2011544778A patent/JP5721637B2/ja not_active Expired - Fee Related
- 2010-01-06 WO PCT/CN2010/070038 patent/WO2010078842A1/zh active Application Filing
- 2010-01-06 MA MA34075A patent/MA33034B1/fr unknown
- 2010-01-06 KR KR20117017931A patent/KR101300540B1/ko active IP Right Grant
- 2010-01-06 HU HUE10729101A patent/HUE035110T2/en unknown
- 2010-01-06 AU AU2010204379A patent/AU2010204379B2/en active Active
- 2010-01-06 DK DK10729101.5T patent/DK2388317T3/da active
- 2010-01-06 PT PT107291015T patent/PT2388317T/pt unknown
- 2010-01-06 BR BRPI1006104A patent/BRPI1006104B8/pt active IP Right Grant
- 2010-01-06 ES ES10729101.5T patent/ES2649021T3/es active Active
-
2011
- 2011-06-23 IL IL213750A patent/IL213750A/en active IP Right Grant
- 2011-07-07 US US13/178,058 patent/US9029142B2/en active Active
- 2011-07-14 ZA ZA2011/05209A patent/ZA201105209B/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002049423A1 (es) * | 2000-12-20 | 2002-06-27 | Universitat Autonoma De Barcelona | Utilizacion conjunta del gen de la insulina y del gen de la glucoquinasa en el desarrollo de aproximaciones terapeuticas para la diabetes mellitus |
US20070219346A1 (en) * | 2002-04-22 | 2007-09-20 | Mcgill University | Glucose sensor and uses thereof |
WO2006043036A2 (en) * | 2004-10-19 | 2006-04-27 | The University Of Newcastle | Treatment of diabetes |
Non-Patent Citations (2)
Title |
---|
U. J. DESAI ET AL: "Phenotypic Correction of Diabetic Mice by Adenovirus-Mediated Glucokinase Expression", DIABETES, vol. 50, no. 10, 1 October 2001 (2001-10-01), pages 2287 - 2295, XP055041275, ISSN: 0012-1797, DOI: 10.2337/diabetes.50.10.2287 * |
V. V. HEREDIA ET AL: "Biochemical Basis of Glucokinase Activation and the Regulation by Glucokinase Regulatory Protein in Naturally Occurring Mutations", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 281, no. 52, 1 January 2006 (2006-01-01), pages 40201 - 40207, XP055041211, ISSN: 0021-9258, DOI: 10.1074/jbc.M607987200 * |
Also Published As
Publication number | Publication date |
---|---|
IL213750A (en) | 2015-11-30 |
CA2749180A1 (en) | 2010-07-15 |
ZA201105209B (en) | 2012-09-26 |
NZ593893A (en) | 2013-02-22 |
MA33034B1 (fr) | 2012-02-01 |
EP2388317A4 (en) | 2012-11-28 |
PT2388317T (pt) | 2017-11-27 |
CN102272296B (zh) | 2012-10-24 |
HUE035110T2 (en) | 2018-05-02 |
CA2749180C (en) | 2017-03-21 |
WO2010078842A1 (zh) | 2010-07-15 |
BRPI1006104A2 (pt) | 2016-02-16 |
ES2649021T3 (es) | 2018-01-09 |
SG172851A1 (en) | 2011-08-29 |
US20110286984A1 (en) | 2011-11-24 |
US9029142B2 (en) | 2015-05-12 |
BRPI1006104B1 (pt) | 2021-04-20 |
JP2012514463A (ja) | 2012-06-28 |
AU2010204379A1 (en) | 2011-07-28 |
EA024878B1 (ru) | 2016-10-31 |
CN102272296A (zh) | 2011-12-07 |
JP5721637B2 (ja) | 2015-05-20 |
AU2010204379B2 (en) | 2014-02-13 |
MX2011007263A (es) | 2011-10-06 |
DK2388317T3 (da) | 2017-11-27 |
KR101300540B1 (ko) | 2013-09-02 |
BRPI1006104B8 (pt) | 2021-05-25 |
IL213750A0 (en) | 2011-07-31 |
KR20110099057A (ko) | 2011-09-05 |
EP2388317A1 (en) | 2011-11-23 |
EP2388317B1 (en) | 2017-08-30 |
AP2011005814A0 (en) | 2011-08-31 |
EA201170917A1 (ru) | 2011-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AP3277A (en) | Gene encoding human glucokinase mutant, enzyme encoded by the same, recombinant vectors and hosts, pharmaceutical compositions and uses thereof, methods for treating and preventing diseases | |
IL251916A0 (en) | Improved amino acid sequences directed against il-6r and polypeptides containing them for the treatment of il-6r-related diseases and disorders | |
IL253038A0 (en) | Preparations and methods for the treatment or prevention of infections. my voice | |
MX359953B (es) | Ácido nucleico que comprende o que codifica un tallo-rizo de histona y una secuencia poli (a) o una señal de poliadenilación para incrementar la expresión de una proteína terapéutica codificada. | |
PH12015502433B1 (en) | Fgf21 mutants and uses thereof | |
WO2010129600A3 (en) | Fgf21 mutants and uses thereof | |
WO2008053444A3 (en) | Treating a respiratory condition with bifidobacterium | |
MY172292A (en) | Vectors and sequences for the treatment of diseases | |
HK1220631A1 (zh) | 用於遞送治療劑的陰離子核心組合物以及製備和使用所述組合物的方法 | |
WO2012048099A3 (en) | Nanoparticle-loaded cells | |
WO2009129246A3 (en) | Compositions and methods for preparing and using same | |
MX2011007930A (es) | Conjugados de insulina cristalina. | |
WO2011052996A3 (en) | Novel lactobacillus plantarum and composition comprising the same | |
WO2010083347A3 (en) | Peptidomimetic macrocycles | |
IL216414A (en) | Polynucleotide encoded into a polypeptide of neurotoxin, a vector and a host cell containing it and its uses for drug preparation | |
EP2148860A4 (en) | CHEMICALS, COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND RELATED DISEASES | |
EP2401264A4 (en) | PEPTOID OLIGOMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | |
NZ703597A (en) | Mutant fragments of ospa and methods and uses relating thereto | |
WO2011075606A3 (en) | Hyperglycosylated polypeptide variants and methods of use | |
WO2012014083A3 (en) | Frataxin mutants | |
ZA201101517B (en) | Compositions for the prophylaxis and treatment of dermatological/mucosal diseases,and uses thereof | |
IL210538A0 (en) | Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunuity | |
WO2011014520A3 (en) | Compounds and compositions as modulators of gpr119 activity | |
EP2453019A4 (en) | GENE THERAPY COMPOSITIONS FOR PREVENTING AND / OR TREATING AUTOIMMUNE DISEASES | |
WO2012102625A3 (en) | Therapeutic composition |